Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Families, Systems & Health : the Journal of Collaborative Family Healthcare|April 26, 2021
Health-related quality of life in parents and partners of people with type 1 diabetes: Development and validation of type 1 diabetes and life (T1DAL) measuresMarisa E Hilliard, Charles G Minard, David G Marrero, et al.
Diabetes Research and Clinical Practice|November 15, 2020
Design and psychometrics for new measures of health-related quality of life in adults with type 1 diabetes: Type 1 Diabetes and Life (T1DAL)Marisa E Hilliard, David G Marrero, Charles G Minard, et al.
Lancet (London, England)|July 2, 2011
Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trialTihamer Orban, Brian Bundy, Dorothy J Becker, et al.
Diabetes Care|December 4, 2013
Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatmentTihamer Orban, Brian Bundy, Dorothy J Becker, et al.
JAMA|June 17, 2020
Effect of Continuous Glucose Monitoring on Glycemic Control in Adolescents and Young Adults With Type 1 Diabetes: A Randomized Clinical TrialLori M Laffel, Lauren G Kanapka, Roy W Beck, et al.
Lancet (London, England)|July 1, 2011
Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trialDiane K Wherrett, Brian Bundy, Dorothy J Becker, et al.
Pediatric Diabetes|April 30, 2025
Continuous Glucose Monitoring Provides Durable Glycemic Benefit in Adolescents and Young Adults with Type 1 Diabetes: 12-Month Follow-Up ResultsKellee M Miller, Colleen Bauza, Lauren G Kanapka, et al.
The Lancet. Diabetes & Endocrinology|March 14, 2014
Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trialMark R Rigby, Linda A DiMeglio, Marc S Rendell, et al.
The Journal of Clinical Investigation|July 21, 2015
Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patientsMark R Rigby, Kristina M Harris, Ashley Pinckney, et al.
Diabetes Care|November 12, 2025
INHALE-1: A Multicenter Randomized Trial of Inhaled Technosphere Insulin in Children With Type 1 DiabetesMichael J Haller, Lauren Kanapka, Roshanak Monzavi, et al.
Pageof 2